Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
ANP32A is a member of the acidic nuclear phosphoprotein 32 (ANP32) family. The biological role of the ANP32 family is extensive, including hormone receptor interactions, enzyme inhibition, cell adhesion, cell transport, gene expression regulation, and apoptotic signaling pathways.
Figure 1. Mammalian ANP32 proteins function in cell-death pathways. (Reilly, et al. 2014)
ANP32A protein is spherical, its amino terminus (N) is rich in leucine repeat domains (LRRs), and LRR is a short-ordered residue of 20-29 in length, arranged in tandem in cytoplasmic, membrane and extracellular proteins. Its presence determines the stable structural and biochemical properties of ANP32A and can mediate interactions between proteins. The carboxy terminus of ANP32A is rich in aspartic acid and threonine, accounting for about 70%, and is strongly acidic. These characteristics allow the ANP32A protein to participate in a variety of biological processes in the cytoplasm and nucleus.
ANP32A is an important component of the acetyltransferase inhibitor complex and is involved in the regulation of chromatin remodeling and transcription. In type I interferon-dependent transcriptional activities, ANP32A is involved in the formation of transcriptional complexes of IFN-activated genes (ISGs), thereby promoting the antiviral activity of cells. ANP32A can also form a multi-subunit complex with HuR protein, regulate the nuclear shuttle of HuR, and ensure the stability and transport process of mRNA. In addition, Sánchez found that a decrease in the expression level of ANP32A can affect the PP2A pathway and play a role in type I spinal cerebellar ataxia.
Negative Regulation of Tumors by ANP32A
Some scholars have performed immunohistochemical staining on ANP32A expression analysis in five pancreatic cancer cell lines and ANP32A in 35 pancreatic cancer tissues. ANP32A was specifically expressed in pancreatic tissue and correlated with the degree of differentiation of pancreatic cancer tissues. This experiment also showed that ANP32A is expressed in the nucleus of pancreatic acinar and ductal. By comparing the expression of ANP32A in five pancreatic cancer cell lines, it was found that ANP32A protein expression was highest in well-differentiated pancreatic cancer HPAC cells. Overexpression of ANP32A in the MaiPaCa2 cell line caused G1 arrest and inhibited cell growth.
In one study, ANP32A was involved in the chromatin remodeling process by immunoblot analysis and genetic assay, confirming that it is a direct target of miR-21. Cell viability was enhanced by knocking out ANP32A in prostate cancer LNCaP cells, whereas overexpression of ANP32A abolished miR-21 mediated effects in the presence of high miR-21 levels. In A172 glioblastoma cells, overexpression of ANP32A compensated for the effects of anti-miR-21 treatment on cell viability and apoptosis. Down-regulation of ANP32A increases the invasiveness of LNCaP cells. These results indicate that down-regulation of ANP32A contributes to the carcinogenic function of miR-21. Conversely, overexpression of ANP32A inhibits the pro-cancer effect of miR-21.
Positive Regulation of ANP32A on Tumor
The researchers used a combination of isotope labeling and two-dimensional liquid chromatography-tandem mass spectrometry to investigate the abnormal protein expression associated with hepatocellular carcinoma in clinical tissues. This method produced a depth-quantitative proteome of 1 360 proteins, of which 267 proteins changed at least 1.5-fold. Proteins that are up-regulated in HCC tissues are involved in regulatory processes such as the granzyme-mediated apoptotic pathway (GzmA pathway). The central component of the GzmA pathway is significantly up-regulated in the SET complex in HCC tissues. Elevated expression of all SET complex components was verified by Western blot. Among them, ANP32A was further studied by immunohistochemical staining using tissue microarrays, which was confirmed to be overexpressed in hepatocellular carcinoma.
ANP32A Promotes Tumor Development through EMT
The progression of most malignancies is accompanied by a loss of epithelial differentiation and a transition to a mesenchymal phenotype. This transformation process is called epithelial-mesenchymal transition (EMT), which exacerbates the viability and invasiveness of many cells and is often considered a prerequisite for tumor invasion and metastasis. During EMT transformation, epithelial markers are reduced and mesenchymal markers are increased. Velmurugan et al. knocked out the expression of endogenous ANP32A in oral squamous cell carcinoma cells and found that the expression levels of Snail, Vimentin, Claudin-1 and other proteins were decreased, while the expression level of E-cadherin protein was increased. The experiment also demonstrated a very significant association between ANP32A and Claudin-1 expression. These results support the notion that ANP32A increases cancer cell invasiveness through the EMT pathway.
ANP32A and Tumor Prognosis
Velmurugan et al. analyzed tissue samples from 259 patients with oral squamous cell carcinoma (OSCC) by tissue microarray and found that ANP32A expression is associated with lymph node metastasis and tumor differentiation. The experiment also showed that the Kaplan-Meier mortality composite curve associated with lymph node staging and ANP32A expression was significantly heterogeneous (P < 0.001 and 0.002, respectively).Similar results were found in the joint mortality curve associated with tumor differentiation and ANP32A expression. Studies to date have shown that overexpression of ANP32A regulates the elevation of COX-2 affecting the prognosis of many tumors, such as pancreatic cancer, oral squamous cell carcinoma. Therefore, indirect suggestion that ANP32A may be an important indicator of poor tumor prognosis, can further track the role of ANP32A in tumor prognosis by in vivo or in vitro experiments.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.